Overview of treatment options for invasive fungal infections

被引：53

作者：

Pound, Melanie W. ^{[1
,2
]}

Townsend, Mary L. ^{[1
,3
]}

Dimondi, Vincent ^{[1
]}

Wilson, Dustin ^{[1
,4
]}

Drew, Richard H. ^{[1
,5
,6
]}

机构：

[1] Campbell Univ, Coll Pharm & Hlth Sci, Buies Creek, NC 27506 USA

[2] New Hanover Reg Med Ctr, Wilmington, NC USA

[3] Durham Vet Affairs Med Ctr, Durham, NC USA

[4] Cape Fear Valley Hlth Syst, Fayetteville, NC USA

[5] Duke Univ, Sch Med, Durham, NC USA

[6] Duke Univ, Med Ctr, Durham, NC USA

来源：

MEDICAL MYCOLOGY | 2011年 / 49卷 / 06期

关键词：

echinocandins; azole antifungals; amphotericin; LIPOSOMAL AMPHOTERICIN-B; CLINICAL-PRACTICE GUIDELINES; IN-VITRO ACTIVITIES; STEM-CELL TRANSPLANT; DOUBLE-BLIND TRIAL; LIPOPEPTIDE ANTIFUNGAL AGENT; ITRACONAZOLE ORAL SOLUTION; CRYPTOCOCCAL MENINGITIS; DISEASES-SOCIETY; NEUTROPENIC PATIENTS;

D O I：

10.3109/13693786.2011.560197

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The introduction of several new antifungals has significantly expanded both prophylaxis and treatment options for invasive fungal infections (IFIs). Relative to amphotericin B deoxycholate, lipid-based formulations of amphotericin B have significantly reduced the incidence of nephrotoxicity, but at a significant increase in drug acquisition cost. Newer, broad-spectrum triazoles (notably voriconazole and posaconazole) have added significantly to both the prevention and treatment of IFIs, most notably Aspergillus spp. (with voriconazole) and the treatment of some emerging fungal pathogens. Finally, a new class of parenteral antifungals, the echinocandins, is employed most frequently against invasive candidal infections. While the role of these newer agents continues to evolve, this review summarizes the activity, safety and clinical applications of agents most commonly employed in the treatment of IFIs.

引用

页码：561 / 580

页数：20

共 241 条

[1]

*3 RIV PHARM, 2009, AMPH PACK INS

[2] A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients [J].

Ally, R ;

Schürmann, D ;

Kreisel, W ;

Carosi, G ;

Aguirrebengoa, K ;

Dupont, B ;

Hodges, M ;

Troke, P ;

Romero, AJ .

CLINICAL INFECTIOUS DISEASES, 2001, 33 (09) :1447-1454

[3] Management of invasive candidal infections: Results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature [J].

Anaissie, EJ ;

Darouiche, RO ;

AbiSaid, D ;

Uzun, O ;

Mera, J ;

Gentry, LO ;

Williams, T ;

Kontoyiannis, DP ;

Karl, CL ;

Bodey, GP .

CLINICAL INFECTIOUS DISEASES, 1996, 23 (05) :964-972

[4] In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model [J].

Andes, D ;

van Ogtrop, M .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) :938-942

[5] In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species [J].

Andes, D. ;

Diekema, D. J. ;

Pfaller, M. A. ;

Bohrmuller, J. ;

Marchillo, K. ;

Lepak, A. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (06) :2497-2506

[6] Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model [J].

Andes, D ;

Stamsted, T ;

Conklin, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) :922-926

[7]

[Anonymous], 2009, CLIN PRACT GUID ONC

[8]

[Anonymous], MICROMEDEX DATABASE

[9] Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species [J].

Antachopoulos, Charalampos ;

Meletiadis, Joseph ;

Sein, Tin ;

Roilides, Emmanuel ;

Walsh, Thomas J. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (03) :881-887

[10] Randomized, double-blind, Multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases [J].

Arathoon, EG ;

Gotuzzo, E ;

Noriega, LM ;

Berman, RS ;

DiNubile, MJ ;

Sable, CA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (02) :451-457

← 1 2 3 4 5 6 7 8 9 10 →